Accounting for Genomic Testing Costs in Cost-Effectiveness Evaluations: Challenges and Lessons Learned from the NICE Single Technology Appraisal of Erdafitinib for Treating Unresectable or Metastatic Urothelial Cancer with FGFR3 Alterations After a PD-1 or PD-L1 Inhibitor
本文未提供摘要，请点击“查看全文”查看完整内容。